# Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer

> **NCT02024633** · PHASE1 · UNKNOWN · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** icotinib
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02024633
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-12
- **Primary completion:** 2015-12
- **Final completion:** 2016-03
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2015-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02024633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02024633, "Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02024633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*